| Autor: |
I. Jahan, N. Papri, R. Ahmed, J. Ahmed, S. Khurshid, P. Biswas, I. Upama, Y. Hamid, I. Hasan, A. Rahman, G. Ara, S. Hayat, Q. Mohammad, Z. Islam |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
International Journal of Infectious Diseases, Vol 130, Iss , Pp S84- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1201-9712 |
| DOI: |
10.1016/j.ijid.2023.04.209 |
| Popis: |
Intro: Guillain-Barre syndrome (GBS), an immune-mediated polyneuropathy with variable clinical manifestation, prognosis and outcome. Despite of the proven efficacy of intravenous immunoglobulin (IVIg), 20% patients remain disabled with 2-19% mortality. Biomarker associated with clinical prognosis and outcome of GBS is needed to improve clinical management and effective treatment at early stage of GBS. In this study, we assessed the association between serum albumin levels, a relatively easily measurable biomarker of health and inflammation, and the clinical prognosis of GBS. Methods: We included 140 GBS patients in a prospective cohort study during 2019-2022 in Bangladesh. Detailed neurological examinations and measurement of serum albumin were done at baseline and pre-defined follow-up. Statistical comparisons between serum albumin and disease prognosis were performed using spearman correlation, ANOVA and student t-test. Findings: The median (IQR) age of 140 patients was 35 (21) years with male predominance (71%); 53 patients treated with IVIg, 29 with plasmapheresis and 58 with supportive care. Severity was higher (88%) and 48 patients required mechanical ventilation (32%). The median of serum albumin was significantly lower in severely affected patients compared to the mild cases (media [IQR]; 39.04 [7.9] vs. 42.14 [5.32], P= 0.001). Serum albumin levels had strong negative correlation with GBS disability score at enrolment (r= -0.663, P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
